drugset / Trial / NCT01194804

E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients

NCT01194804

NaSingle-groupOpen-labelTreatment

Summary

The objective of this study was to assess the long-term safety and efficacy of eculizumab in hemolytic PNH patients who completed the 4-week screening and 12-week treatment period of the C07-001 study. In addition, pharmacokinetic and pharmacodynamic assessments of eculizumab were conducted.

Timeline

Start
2008-04
Primary completion
2010-09
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Eculizumab Monoclonal antibody 900 mg Intravenous